Enochian BioSciences’ CEO Letter to Shareholders
April 03, 2023 09:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Accelerated Pre-Investigational New Drug (Pre-IND) submission to the US Food and Drug Administration (FDA) for potential cancer...
Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher
March 29, 2023 09:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy...
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements
March 13, 2023 08:30 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual...
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022
February 23, 2023 16:04 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Feb. 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On February 16, 2023, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC...
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022
November 30, 2022 17:20 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On November 23, 2022, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC...
Enochian BioSciences Forges Ahead With Focused Approach, Promising Future
October 24, 2022 08:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Enochian BioSciences (the Company) recently announced significant progress toward re-prioritizing its focus on curing some of the...
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-K
October 21, 2022 17:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 21, 2022 (GLOBE NEWSWIRE) -- On October 17, 2022, Enochian BioSciences, Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating...
Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform
October 17, 2022 08:30 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Today, Enochian BioSciences (the Company) announced that it was awarded a U.S. patent for its proprietary cancer treatment platform that could...
Enochian BioSciences Appoints Dr. Richard Whitley As Senior Scientific Advisor
July 25, 2022 10:15 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham...
Enochian BioSciences Announces Findings From A Rigorous Internal Review of Scientific Data
July 01, 2022 17:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, July 01, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—In recent days, Enochian BioSciences (the Company) has conducted a rigorous internal review of scientific data to give partners and...